US2013202534A1PendingUtilityA1

Pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency

Assignee: ASTELLAS PHARMA INCPriority: Jan 11, 2008Filed: Mar 15, 2013Published: Aug 8, 2013
Est. expiryJan 11, 2028(~1.5 yrs left)· nominal 20-yr term from priority
A01K 2227/105A01K 2227/10G01N 2500/00G01N 33/5082A01K 2207/20A01K 2267/03A61K 49/0008A61P 13/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pathologic animal model characterized in that a pain or discomfort behavior and urinary frequency are induced by administering a stimulative substance into the testes of a small-sized mammal, and a screening method for a therapeutic agent for pelvic pain syndrome, particularly non-bacterial chronic prostatitis, which comprises administering a test substance to the pathologic animal model and measuring pain or discomfort behaviors and/or urinary frequency.

Claims

exact text as granted — not AI-modified
1 .- 4 . (canceled) 
     
     
         5 . A screening method for therapeutic agents for a pelvic pain syndrome, comprising:
 administering acetic acid or nerve growth factor (NGF) into the testes of a small-sized  mammal; and   administering a test substance and measuring pain or discomfort behaviors and/or urinary frequency.   
     
     
         6 . The screening method for therapeutic agents described in  claim 5 , wherein the pelvic pain syndrome is urological pain syndrome. 
     
     
         7 . The screening method for therapeutic agents described in  claim 6 , wherein the urological pain syndrome is non-bacterial chronic prostatitis. 
     
     
         8 . The screening method described in  claim 7 , which comprises administering the test substance before or after administration of a stimulative substance into the testes of the pathologic animal model, and selecting the test substance that improves the pain or discomfort behavior and/or urinary frequency.

Join the waitlist — get patent alerts

Track US2013202534A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.